In a report released today, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on PolarityTE Inc (NASDAQ: COOL), with a price target of $65. The company’s shares opened today at $18.35, close to its 52-week low of $15.21.
Piros observed:
“: We are reiterating our Overweight rating and 12-month price target of $65/share on PolarityTE following 3Q18 financial results. Additional clinical outcomes data will be presented at the Conference, taking place from Sept.28-Oct.1 in Chicago. PolarityTE will begin trading under the ticker “PTE”. Our financial model and estimates will be updated following the 10-Q release.”
According to TipRanks.com, Piros is ranked 0 out of 5 stars with an average return of -6.0% and a 44.8% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PolarityTE Inc with a $65 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $41.22 and a one-year low of $15.21. Currently, PolarityTE Inc has an average volume of 903.5K.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of COOL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PolarityTE, Inc. engages in the regenerative medicine and tissue engineering platform. The firm seeks to develop and obtain regulatory approval for technology that will utilize a patient’s own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves.
